Marker Therapeutics, Inc.

Category: Media Coverage

Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.

Is TapImmune’s Cancer Vaccine the Real Deal?

TapImmune released some interesting results this week from a Phase I trial conducted at the Mayo Clinic that will add some spice to that discussion.
Read More

Ovarian and Breast Cancer Vaccine Candidate Posts Positive Clinical Trial Results

TPIV200 vaccine candidate showed 90% of patients developed robust and durable antigen-specific immune responses against FRa.
Read More

Are Cancer Vaccines the Future of Treatment?

TapImmune, an immuno-oncology company in Florida is currently clinically testing a vaccine specifically for triple-negative breast and ovarian cancer.
Read More

Off-the-Shelf Vaccine Investigated in Phase II Study of TNBC for Recurrence Prevention

A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer (TNBC).
Read More

Breast Cancer Vaccine Candidate Launches Phase 2 Clinical Study

Precision Vaccination highlighted our cancer vaccine, TPIV200 for treating triple-negative breast cancer.
Read More

Cancer Vaccine to Prevent Breast, Ovarian Cancer Recurrence Could be Close

Peter Hoang, President and CEO of TapImmune, is enthusiastic about a cancer vaccine under development by TapImmune that could help prevent recurrence of such cancers in women.
Read More

TapImmune Brings Therapeutic Vaccines into the Clinic for Ovarian, Breast Cancer

With new innovations and breakthroughs in the field of immunotherapy TapImmune CEO & President, Peter Hoang has been amazed by the change of pace within the field.
Read More

TPIV200

TPIV 200 is a vaccine that the immuno-oncology company TapImmune is developing as a treatment for platinum-chemotherapy resistant ovarian cancer or triple-negative breast cancer.
Read More

Immunovaccine’s Lncyte-Partnered Cancer Vaccine Shows Early Promise in Ovarian Cancer

TapImmune’s lead candidate, TPIV200, a multiple-epitope anti-folate receptor alpha (FRα) immunotherapy, with an FDA orphan drug designation, has paired up with AstraZeneca’s checkpoint inhibitor Imfinzi in platinum-resistant ovarian cancer patients.
Read More

TapImmune Inc. (NASDAQ: TPIV) CEO Interview

Tapimmune Inc. President & CEO, Peter Hoang, participates in an interview with The Wall Street Analyzer. Take a listen.
Read More